Wilson Sonsini's 2024 Technology and Life Sciences PIPE and RDO Report provides an analysis of 205 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based technology and life sciences firms from January 1 to December 31, 2024. This report focuses exclusively on transactions where the company secured a minimum of $10 million and completed at least one closing during 2024.

After several years of low capital market activity, 2024 experienced a notable uptick compared to 2022 and 2023. We are hopeful that the capital markets will continue to thaw. Nevertheless, given the market volatility and uncertainty that remain, we expect that companies may continue to explore alternatives to traditional underwritten offerings as a way to meet their financing needs.

Key insights from our analysis:

• Increase in PIPE Transactions: 2024 saw a 38.1% rise in PIPE transactions, which may be driven by the SEC’s “baby shelf” rule, while RDOs remained stable. A significant portion of PIPEs was completed by companies with a public float under $75 million.
• RDOs Priced at a Premium: The average premium for RDOs in 2024 was 2.0%, reflecting a trend of higher pricing compared to previous years, potentially reflecting marginally stronger investor sentiment.
• Decline in Insider Participation: Insider participation dropped to 18.5% in 2024, down from 27.6% in 2023. The drop was especially notable in technology transactions, which saw a 50% reduction. This decrease suggests a growing confidence among outside investors, indicating a potential shift in market dynamics as these investors typically require fewer reporting and approval hurdles compared to insider-led financings.

Click here to read the report.